High efficiency of the pan-PI3K/mTOR inhibitor, PQR-309, in MCL

被引：0
|
作者：
Kvint, R. [1 ]
Zimmermann, Y. [1 ]
Hutter, G. [1 ]
Hiddemann, W. [1 ]
Dreyling, M. [1 ]
机构：
[1] Klinikum Univ Munchen, Med Klin 3, Munich, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P524
引用
收藏
页码：153 / 154
页数：2
相关论文
共 50 条
  • [1] Concomitant administration of acid reducing agents can impact the pharmacokinetics of the balanced pan-PI3K and mTOR inhibitor PQR309
    Jorga, Karin
    Huehn, Eva
    Fraczkiewicz, Grace
    Schmitz, Debora
    Fabbro, Doriano
    Dimitrijevic, Sasa
    CANCER RESEARCH, 2016, 76
  • [2] PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability
    Cmiljanovic, Vladimir
    Ettlin, Robert A.
    Beautils, Florent
    Dieterle, Walter
    Hillmann, Petra
    Mestan, Juergen
    Melone, Anna
    Bohnacker, Thomas
    Lang, Marc
    Cmiljanovic, Natasa
    Giese, Bernd
    Hebeisen, Paul
    Wymann, Matthias P.
    Fabbro, Doriano
    CANCER RESEARCH, 2015, 75
  • [3] PQR309: Structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor
    Cmiljanovic, Vladimir
    Cmiljanovic, Natasa
    Marone, Romina
    Beaufils, Florent
    Zhang, Xuxiao
    Zvelebil, Marketa
    Hebeisen, Paul
    Lang, Marc
    Mestan, Juergen
    Melone, Anna
    Bohnacker, Thomas
    Gaudio, Eugenio
    Tarantelli, Chiara
    Bertoni, Francesco
    Ritschard, Reto
    Pretre, Vincent
    Wicki, Andreas
    Fabbro, Doriano
    Hillmann, Petra
    Williams, Roger
    Giese, Bernd
    Wymann, Matthias P.
    CANCER RESEARCH, 2015, 75
  • [4] Exploring intermittent dosing schedules for the Pan PI3K/mTor inhibitor PQR309
    Jorga, Karin
    Schmitz, Debora
    Cmiljanovic, Natasa
    Fabbro, Doriano
    Dimitrijevic, Sasa
    CANCER RESEARCH, 2016, 76
  • [5] Clinical development of voxtalisib: a pan-PI3K/mTOR inhibitor
    Munakata, Wataru
    Tobinai, Kensei
    LANCET HAEMATOLOGY, 2018, 5 (04): : E134 - E135
  • [6] Buparlisib is a brain penetrable pan-PI3K inhibitor
    Mark C. de Gooijer
    Ping Zhang
    Levi C. M. Buil
    Ceren H. Çitirikkaya
    Nishita Thota
    Jos H. Beijnen
    Olaf van Tellingen
    Scientific Reports, 8
  • [7] Buparlisib is a brain penetrable pan-PI3K inhibitor
    de Gooijer, Mark C.
    Zhang, Ping
    Buil, Levi C. M.
    Citirikkaya, Ceren H.
    Thota, Nishita
    Beijnen, Jos H.
    van Tellingen, Olaf
    SCIENTIFIC REPORTS, 2018, 8
  • [8] Relevant skin exposure after topical application of the pan-PI3K/mTOR inhibitor bimiralisib
    Schmitz-Rohmer, Debora
    Streefkerk, Henk Johann
    Rolli, Melanie
    Legouffe, Raphael
    Rissmann, Robert
    Vermeer, Maarten
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB102 - AB102
  • [9] Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer
    Geuna, Elena
    Milani, Andrea
    Martinello, Rossella
    Aversa, Caterina
    Valabrega, Giorgio
    Scaltriti, Maurizio
    Montemurro, Filippo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (03) : 421 - 431
  • [10] Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors
    Machacek, Matthias
    Renaud, Lionel
    Dimitrijevic, Sasa
    Schmitz, Debora
    Ivanova, Elena
    Jorga, Karin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345